NDA News

CanalLotus Biotech news and insights

FDA Approves Osvyrti (denosumab-desu), a Biosimilar to Prolia

RALEIGH, N.C., Nov. 20, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies,

Latest News NDA News 1064
• Read All

FDA Approves Jubereq (denosumab-desu), a Biosimilar to Xgeva

RALEIGH, N.C., Nov. 20, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies,

Latest News NDA News 1076
• Read All

FDA Grants Accelerated Approval to Hyrnuo (sevabertinib) for Non-Squamous Non-Small Cell Lung Cancer

On November 19, 2025 -- the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advan

Latest News NDA News 1068
• Read All

FDA Approves Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

PASADENA, Calif.–(BUSINESS WIRE)–Nov. 18, 2025 -- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved Redemplo (plozasiran), a

Latest News NDA News 928
• Read All

FDA Approves Komzifti (ziftomenib) for the Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

SAN DIEGO and TOYKO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the U.S. Food and Drug Administration (FDA) has granted

Latest News NDA News 956
• Read All

FDA Approves Kygevvi (doxecitine and doxribtimine) for the Treatment of Thymidine Kinase 2 Deficiency

ATLANTA, GA, November 3, 2025 -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that Kygevvi has been granted approval by the U.S. Food and Drug Administration (FDA)

Latest News NDA News 1001
• Read All

FDA Approves Lynkuet (elinzanetant) for Moderate to Severe Hot Flashes Due to Menopause

WHIPPANY, N.J., October 24, 2025 -- Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) target

Latest News NDA News 1419
• Read All

FDA Approves Javadin (clonidine hydrochloride) Oral Solution for the Treatment of Hypertension

Woburn, MA - October 24, 2025 -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Javadin (clonidine hydrochloride) oral solution, the only F

Latest News NDA News 1226
• Read All

FDA Approves Contepo (fosfomycin) for Injection for the Treatment of Complicated Urinary Tract Infections

October 22, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Contepo (fosfomycin) for injection for the treatment of patients 18 years of age and older with complicated urinary tract i

Latest News NDA News 1847
• Read All

FDA Approves Epioxa (riboflavin 5’-phosphate) Ophthalmic Solution for the Treatment of Keratoconus

Aliso Viejo, CA – October 20, 2025 -- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di

Latest News NDA News 935
• Read All

FDA Approves Ferabright (ferumoxytol injection) Contrast Agent for Magnetic Resonance Imaging of the Brain

Woburn, MA — October 17, 2025 -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ferabright (ferumoxytol injection), the first and only iron

Latest News NDA News 1423
• Read All

FDA Approves Jascayd (nerandomilast) to Treat Idiopathic Pulmonary Fibrosis

October 9, 2025 -- Boehringer Ingelheim’s Jascayd (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) as an oral treatment option for idiopathic pulmonary fibrosis

Latest News NDA News 1555
• Read All
News
Gloved hands holding a globe, global clinical trial drug sourcing
- CanalLotus Biotech -
Int'l Clinical Service Expert

We are the leader
Because of our professionism

WhatsApp Service QR code